BioCryst & Celgene Suffer English Funding Setback For Rare Disease Drugs
NICE’s Recommendations Are Out For Consultation until 28 July
Orladeyo and Inrebic have been approved in Great Britain but they will not be available under the National Health Service unless their manufacturers can convince the health technology assessment body, NICE, that their products are cost-effective.
